Currently Viewing:
Newsroom
Currently Reading
More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma
September 21, 2018 – Samantha DiGrande
Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma
September 20, 2018 – David Bai
Are Integrated Practice Units Working in Breast Cancer Clinical Pathways?
September 18, 2018 – Allison Inserro
Keytruda Earns Priority Review as Monotherapy in NSCLC
September 17, 2018 – Samantha DiGrande
Twice-Yearly MRIs Superior at Finding Early Breast Cancer in High-Risk Women
September 17, 2018 – Allison Inserro
NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care
September 16, 2018 – Jaime Rosenberg
Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?
September 15, 2018 – Jaime Rosenberg
NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use
September 14, 2018 – Samantha DiGrande
This Week in Managed Care: September 14, 2018
September 14, 2018

More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma

Samantha DiGrande
Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC. 
Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC. 

“The US Agency for Healthcare Research and Quality noticed that there were many treatments available for basal cell carcinoma and were unsure of how effective they were. In order to improve treatment and health-policy decisions, a systematic appraisal and analysis of the existing literature was needed,” said Aaron Drucker, MD, ScM, in an interview with Healio Internal Medicine.

Researchers analyzed 40 randomized trials and 5 nonrandomized studies that investigated 18 common interventions for treating BCC. Data were reviewed and compared on recurrence, histologic clearance, clinical clearance, cosmetic outcomes, quality of life, and mortality for each intervention. According to the authors, this is the first analysis to compare more than 1 intervention simultaneously. 

Collected data showed that estimated recurrence rates were similar for excision (3.8% [95% CI, 1.5%-9.5%]), Mohs surgery (3.8% [95% CI, 0.7%-18.2%]), curettage and diathermy (6.9% [95% CI, 0.9%-36.6%]), and external-beam radiation (3.5% [95% CI, 0.7%-16.8%]). 

However, researchers also noted that recurrence rates were higher for cryotherapy (22.3% [95% CI, 10.2%-42.0%]), curettage and cryotherapy (19.9% [95% CI, 4.6%-56.1%]) 5-flurouracil (18.8% [95% CI, 10.1%-32.5%]), imiquimod (14.1% [95% CI, 5.4%-32.4%]), photodynamic therapy using methyl-aminolevulinic acid (18.8% [95% CI, 10.1%-32.5%]) or aminolevulinic acid (16.6% [95% CI, 7.5%-32.8%]). Unfortunately, there were not enough data to determine the interventions’ effects on quality of life and mortality. 

The researchers recommended that a “better monitoring of population trends in BCC would help prioritize research on the most consequential groups of patients and types of cancer.” Additionally, it was noted that in order for clinicians, patients, and payers to make informed decisions about treating BCC, more trials are necessary to compile more evidence. 

“When discussing treatment options with patients for shared decision-making, clinicians should explain that there is uncertainty around the relative effectiveness of the many different treatments,” said Drucker.

Reference

Drucker A, Adam G, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis [published online September 18, 2018]. Ann Intern Med. doi: 10.7326/M18-0678.

Related Articles

Sonidegib Approved for Basal Cell Carcinoma
Avelumab Gains Accelerated Approval for Urothelial Carcinoma
Pembrolizumab Gets Priority Review for Merkel Cell Carcinoma
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up